Want to see DLHC full AI Analyst Report?
DLHC Stock Chart & Stats
$5.09
$0.02(0.39%)
At close: 4:00 PM EDT
$5.09
$0.02(0.39%)
Day’s Range― - ―
52-Week Range$4.45 - $8.10
Previous CloseN/A
Volume2.15K
Average Volume (3M)27.65K
Market Cap
$65.65M
Enterprise Value$217.00
Total Cash (Recent Filing)$235.00K
Total Debt (Recent Filing)$141.14M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Dec 07, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding14,493,035
10 Day Avg. Volume37,306
30 Day Avg. Volume27,646
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)0.72
Price to Sales (P/S)0.24
P/FCF Ratio3.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$7.00Price Target Upside37.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$209.38M
Bulls Say, Bears Say
Bulls Say
Navy Cyberspace IDIQ Expands Federal Technical-services OpportunityThe Navy vehicle broadens DLH’s addressable federal work beyond healthcare and creates access to future task orders in cybersecurity, engineering and technology integration. While awards are not guaranteed, it strengthens positioning in mission-critical services with durable government demand.
Two-year NIH Extension Improves Revenue VisibilityThe extension preserves an established customer relationship and supports a more visible base of public-health revenue during contract transitions. Its sole-source structure also reduces near-term recompete risk and provides time to develop additional federal opportunities.
Positive Cash Flow And Resumed Debt Reduction Support Financial FlexibilityPositive free cash flow gives DLH internal resources to service debt and invest in operations despite weaker revenue. Continued deleveraging could lower financial risk and improve resilience, provided management converts its EBITDA target into sustained cash repayment.
Bears Say
Contract Transitions And Completions Are Materially Shrinking RevenueThe decline reflects loss or transfer of substantial work rather than a minor fluctuation, weakening operating leverage and earnings quality. Replacing the volume requires successful new awards and timely starts, leaving the business exposed during the transition period.
Elevated Leverage Limits Room For Prolonged Earnings WeaknessDebt remains high relative to the equity base while profitability has deteriorated, increasing sensitivity to contract delays or further margin pressure. Although repayment has resumed, leverage can constrain investment flexibility and amplify the consequences of weaker federal-service demand.
Federal Health Reprioritization And Procurement Delays Threaten Growth TimingDLH depends heavily on federal budgets and procurement schedules, so reduced health priorities could pressure portions of its core portfolio. Even with a healthy pipeline, protests and funding interruptions can defer starts, delaying revenue replacement and weakening visibility.
DLH Holdings News
DLHC FAQ
What was DLH Holdings’s price range in the past 12 months?
DLH Holdings lowest stock price was $4.45 and its highest was $8.10 in the past 12 months.
What is DLH Holdings’s market cap?
DLH Holdings’s market cap is $65.65M.
When is DLH Holdings’s upcoming earnings report date?
DLH Holdings’s upcoming earnings report date is Dec 07, 2026 which is in 104 days.
How were DLH Holdings’s earnings last quarter?
DLH Holdings released its earnings results on Jul 29, 2026. The company reported -$1.16 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.99.
Is DLH Holdings overvalued?
According to Wall Street analysts DLH Holdings’s price is currently Undervalued.
Does DLH Holdings pay dividends?
DLH Holdings does not currently pay dividends.
What is DLH Holdings’s EPS estimate?
DLH Holdings’s EPS estimate is -0.28.
How many shares outstanding does DLH Holdings have?
DLH Holdings has 14,493,035 shares outstanding.
What happened to DLH Holdings’s price movement after its last earnings report?
DLH Holdings reported an EPS of -$1.16 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -9.259%.
Which hedge fund is a major shareholder of DLH Holdings?
Currently, no hedge funds are holding shares in DLHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DLH Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (37.52% Upside)
$7.00 (37.52% Upside)
Blogger Sentiment
Bearish
DLHC Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $591.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.88%
Trailing 12-Months
Company Description
DLH Holdings
DLH Holdings Corp., headquartered in Atlanta, Georgia, was established in 1969 and operated as TeamStaff, Inc. until its name change in June 2012. The company specializes in offering a range of technology-enabled business process outsourcing, comprehensive program management solutions, and public health research and analytics services throughout the United States, with a primary focus on the federal health services market. A significant portion of DLH's work involves defense and veterans' health, where it delivers integrated healthcare, technology, and logistical support. Key clients in this sector include the Department of Veterans Affairs (VA), the Defense Health Agency, the Tele-medicine and Advanced Technology Research Center, the Navy Bureau of Medicine and Surgery, and the Army Medical Research and Material Command. Additionally, the company provides diverse human services and solutions, covering areas such as rigorous monitoring and evaluation, efficient electronic medical records migration, robust data collection and management, and thorough nutritional and social health assessments. It also offers expert IT system architecture design, strategic migration planning, and continuous maintenance services. In the sphere of public health and life sciences, DLH undertakes crucial initiatives like clinical trials, epidemiological studies, and disease prevention. It actively promotes health among underserved and at-risk communities through the creation of impactful strategic communication campaigns, research into emerging health trends, in-depth health informatics analyses, and the application of proven best practices.
DLHC Company Deck
DLHC Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call communicated a mixed picture: material near-term financial headwinds with a steep year-over-year revenue decline (~33.5%) and a sharp drop in adjusted EBITDA (~43.6%), largely driven by program transitions to small business set-asides and contract completions. Offsetting these negatives, management reported margin resilience (9% adjusted EBITDA margin), positive free cash flow (~$3.8M), resumed deleveraging (debt reduced to $132.7M), a two-year NIH contract extension adding revenue visibility, recognition for technology capabilities, and an improving pipeline as delayed procurements return to market. Risks remain around federal health reprioritization and typical government procurement timing uncertainty, but the company appears to be stabilizing its cost structure and positioning for upcoming opportunities.View all DLHC earnings summariesDLHC Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$7.00
▲(37.52% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
36.95% Insiders
7.37% Mutual Funds
8.29% Other Institutional Investors
43.49% Public Companies and
Individual Investors






